Project profile — COVID-19 vaccine research and development

• Asia, regional (20.00%)
• Oceania, regional (20.00%)
• Europe, regional (20.00%)
• Africa, regional (20.00%)
• America, regional (20.00%)

• Health: COVID-19 control (12264) (90.00%)
• Conflict Prevention And Resolution, Peace And Security: Security system management and reform (15210) (10.00%)

• Gender equality (significant objective)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Disaster Risk Reduction(DRR) (principal objective)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• Nutrition (not targeted)
• ICT as a tool for development (not targeted)

This project aims to support the Coalition for Epidemic Preparedness Innovations (CEPI) to help the development, manufacture, and ultimate distribution of up to 1.2 billion COVID-19 vaccine(s) through a fair allocation system within 12 to18 months. Project activities include: (1) supporting research and development of up to 5 vaccine candidates; and (2) supporting manufacturing and distribution of up to 1.2 billion vaccine doses by 2021.

The expected outcomes of this project include: (1) strengthened global preparedness for known epidemic and pandemic threats; (2) strengthened global response to emerging pandemic threats; and (3) improved collaboration between public and private pandemic preparedness and response stakeholders.

Results achieved as of May 2022 include: (1) developed 8 COVID-19 vaccine candidates with CEPI support. 7 of them progressed into Phase II or III clinical trials; (2) the World Health Organization authorized 3 COVID-19 vaccine candidates (Astra Zeneca, Moderna and Novavax) for emergency use; (3) 5 candidates (AZ/Uni Oxford, CureVac, Clover, Moderna and Novavax,) published primary endpoint analysis of pivotal trial (AZ/Uni Oxford, Moderna, Novavax, CureVac and Clover); and (4) delivered over 900 million COVID-19 vaccine doses in 2021 (reaching 95% of target).

• Proactive disclosure
• Related activities: COVID-19 Vaccine Research and Development